Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

ABSTRACT Tuberculosis is a global health problem that causes the death of approximately 1.5 million people worldwide each year (WHO, p. 1–126, Global Tuberculosis Report, 2015). Treatment of drug-susceptible tuberculosis requires combination antimicrobial therapy with a minimum of four antimicrobial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christopher A. Kerantzas, William R. Jacobs
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2017
Materias:	Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/718788eb54c14dd5981a50ca56d82753
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:718788eb54c14dd5981a50ca56d82753
record_format	dspace
spelling	oai:doaj.org-article:718788eb54c14dd5981a50ca56d827532021-11-15T15:51:00ZOrigins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application10.1128/mBio.01586-162150-7511https://doaj.org/article/718788eb54c14dd5981a50ca56d827532017-05-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01586-16https://doaj.org/toc/2150-7511ABSTRACT Tuberculosis is a global health problem that causes the death of approximately 1.5 million people worldwide each year (WHO, p. 1–126, Global Tuberculosis Report, 2015). Treatment of drug-susceptible tuberculosis requires combination antimicrobial therapy with a minimum of four antimicrobial agents applied over the course of 6 months. The first instance of combination antimicrobial therapy applied to tuberculosis was the joint use of streptomycin and para-aminosalicylic acid as documented by the Medical Research Council of the United Kingdom in 1950. These antimicrobial drugs were the product of many decades of investigation into both organism-derived antibiotics and synthetic chemotherapy and were the first agents in those respective categories to show substantial clinical efficacy and widespread use for tuberculosis. The events leading to the discovery and application of these two agents demonstrate that investments in all aspects of research, from basic science to clinical application, are necessary for the continued success of science in finding treatments for human disease. This observation is especially worth considering given the expanded role that combination therapy may play in combating the current rise in resistance to antimicrobial drugs.Christopher A. KerantzasWilliam R. JacobsAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 8, Iss 2 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Microbiology QR1-502
spellingShingle	Microbiology QR1-502 Christopher A. Kerantzas William R. Jacobs Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
description	ABSTRACT Tuberculosis is a global health problem that causes the death of approximately 1.5 million people worldwide each year (WHO, p. 1–126, Global Tuberculosis Report, 2015). Treatment of drug-susceptible tuberculosis requires combination antimicrobial therapy with a minimum of four antimicrobial agents applied over the course of 6 months. The first instance of combination antimicrobial therapy applied to tuberculosis was the joint use of streptomycin and para-aminosalicylic acid as documented by the Medical Research Council of the United Kingdom in 1950. These antimicrobial drugs were the product of many decades of investigation into both organism-derived antibiotics and synthetic chemotherapy and were the first agents in those respective categories to show substantial clinical efficacy and widespread use for tuberculosis. The events leading to the discovery and application of these two agents demonstrate that investments in all aspects of research, from basic science to clinical application, are necessary for the continued success of science in finding treatments for human disease. This observation is especially worth considering given the expanded role that combination therapy may play in combating the current rise in resistance to antimicrobial drugs.
format	article
author	Christopher A. Kerantzas William R. Jacobs
author_facet	Christopher A. Kerantzas William R. Jacobs
author_sort	Christopher A. Kerantzas
title	Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
title_short	Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
title_full	Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
title_fullStr	Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
title_full_unstemmed	Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
title_sort	origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application
publisher	American Society for Microbiology
publishDate	2017
url	https://doaj.org/article/718788eb54c14dd5981a50ca56d82753
work_keys_str_mv	AT christopherakerantzas originsofcombinationtherapyfortuberculosislessonsforfutureantimicrobialdevelopmentandapplication AT williamrjacobs originsofcombinationtherapyfortuberculosislessonsforfutureantimicrobialdevelopmentandapplication
_version_	1718427405489537024

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

Ejemplares similares